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Apoptosis, necrosis, and inflammation are hallmarks of
cisplatin nephrotoxicity; however, the role and mechanisms
of necrosis and inflammation remains undefined. As
poly(ADP-ribose) polymerase 1 (PARP1) inhibition or its gene
deletion is renoprotective in several renal disease models,
we tested whether its activation may be involved in cisplatin
nephrotoxicity. Parp1 deficiency was found to reduce
cisplatin-induced kidney dysfunction, oxidative stress, and
tubular necrosis, but not apoptosis. Moreover, neutrophil
infiltration, activation of nuclear factor-jB, c-Jun N-terminal
kinases, p38 mitogen-activated protein kinase, and
upregulation of proinflammatory genes were all abrogated
by Parp1 deficiency. Using proximal tubule epithelial cells
isolated from Parp1-deficient and wild-type mice and
pharmacological inhibitors, we found evidence for a
PARP1/Toll-like receptor 4/p38/tumor necrosis factor-a axis
following cisplatin injury. Furthermore, pharmacological
inhibition of PARP1 protected against cisplatin-induced
kidney structural/functional damage and inflammation. Thus,
our findings suggest that PARP1 activation is a primary signal
and its inhibition/loss protects against cisplatin-induced
nephrotoxicity. Targeting PARP1 may offer a potential
therapeutic strategy for cisplatin nephrotoxicity.
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Cisplatin is one of the most commonly used drugs for the
treatment of malignant tumors in testis, ovary, bladder, head
and neck, breast, and many other tissues/organs.1–3 Although
effective, the use of cisplatin is limited by its severe side
effects in normal tissues; among them, the major side effect
during cisplatin treatment is nephrotoxicity. After cisplatin
treatment, approximately one-third of the patients develop
renal dysfunction, resulting in acute renal failure.2–4 Kidney
tubular cell death is recognized as a major pathogenic factor
during cisplatin nephrotoxicity. In cultured kidney tubule
epithelial cells in vitro both apoptotic and necrotic cell death
are dependent on cisplatin concentration, whereas in animal
models both cell death types are simultaneously induced in
kidney tubules after cisplatin injection.5,6 Recent studies
have focused on the mechanisms of apoptosis induced by
cisplatin in kidney tubular cells,7–9 and much less on necrotic
pathways. Cisplatin nephrotoxicity is also associated with a
robust inflammatory response, contributing to the induction
of kidney tubular damage and kidney dysfunction under the
pathological condition.10,11 Although a critical role for tumor
necrosis factor-a (TNF-a)10 and Toll-like receptor 4 (TLR4)11
in the proinflammatory response triggered by cisplatin has
been established using pharmacological inhibitors, anti-
bodies, or gene deletion, the regulation of the inflammatory
response remains incompletely understood.
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is an
important nuclear enzyme that regulates protein functions by
poly(ADP-ribosyl)ation and gene expression as a transcrip-
tion cofactor. PARP1 catalyzes the transfer of ADP-ribose
from nicotinamide adenine dinucleotide (NADþ ) and
conjugates PAR onto various proteins and PARP1 itself, thus
leading to a variety of physiological processes, including
modulation of protein functions and promotion of protein–
protein interactions.12,13 In addition, the role of PARP1 as a
transcriptional regulator is confirmed by genetic or pharma-
cological inhibition, demonstrating its influence on the
expression of inflammatory genes, including TNF-a, inter-
leukin-1b (IL-1b), IL-6, intercellular adhesion molecule-1
(ICAM-1), and TLR4.14–16 Alternatively, the activation of
PARP1 is required for DNA repair, but excessive activation
leads to necrotic cell death by depletion of intracellular
adenosine triphosphate (ATP).17,18 Previous reports from us
and others have demonstrated that PARP1 inhibition or gene
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deletion is renoprotective against ischemia/reperfusion,19,20
diabetes,21 and ureteral obstruction.22 As necrosis and
inflammation are hallmarks of cisplatin nephrotoxixity, we
hypothesized that PARP1 activation may be required for
cisplatin nephrotoxicity. To investigate this hypothesis, we
used a cisplatin-induced kidney injury model and assessed
kidney dysfunction, tissue morphology, apoptosis/necrosis,
neutrophil infiltration, and inflammatory gene expression
in Parp1-knockout (KO) and -wild-type (WT) mice. To
extend these findings in a clinical context, we tested a
pharmacological inhibitor of PARP1 in cisplatin nephro-
toxicity. Our results verify that PARP1 is an important
mediator of cisplatin-induced kidney tubular necrosis and
inflammation.
RESULTS
Kidney PARP1 expression and activation is induced during
cisplatin nephrotoxicity
To determine the role of PARP1 in cisplatin nephrotoxicity,
we first assessed the expression and activation of PARP1 by
western blot analysis in WT kidneys. After cisplatin injection,
the expressions of both full-length and cleaved form of
PARP1 were markedly increased (Figure 1a–c). As catalytic
activation of PARP1 adds PAR polymers to itself, the
measurement of PARP1 activation was accomplished using
western blot analysis of the total poly(ADP-ribosyl)ated
PARP1 level. In addition to the increase in PARP1
expression observed, PARP1 activation was markedly
increased after cisplatin injection (Figure 1a and d). As
expected, in Parp1-KO kidneys, neither PARP1 expression
nor activation was detectable during cisplatin nephrotoxi-
city (Figure 1a).
Loss of PARP1 decreases kidney dysfunction and tubular
necrosis, but not apoptosis, during cisplatin nephrotoxicity
To explore whether PARP1 contributes to cisplatin nephro-
toxicity, we monitored kidney function in Parp1-KO and
-WT mice by measuring plasma creatinine and blood urea
nitrogen concentration. As shown in Figure 2a and b, WT
mice developed severe kidney dysfunction at 2 days and
persisted to 5 days after cisplatin injection. By comparison,
Parp1-KO mice had significantly better kidney function.
Similarly, kidneys of WT mice showed severe tubular damage
in the cortex and outer medulla, as evaluated by tubular
necrosis, cast formation, and tubular dilation, whereas this
damage was reduced in kidneys of Parp1-KO mice (Figure 2c
and d, and Supplementary Figure S1 online). These data
indicate that PARP1 contributes to functional and histolo-
gical damage after cisplatin-induced kidney injury. As PARP1
stimulates a selective necrotic cell death via ATP deple-
tion,17,20 we next analyzed ATP levels in Parp1-KO and -WT
kidneys. After cisplatin injection, the ATP levels were
significantly decreased from day 2 in WT kidneys, whereas
the decrease was markedly reduced in Parp1-KO kidneys
(Figure 2e). To test whether PARP1 contributes to cisplatin-
induced apoptosis, we performed western blot analysis for
cleaved caspase-3 expression and terminal deoxynucleotidyl
transferase–mediated dUTP nick end labeling (TUNEL) assay
for DNA fragmentation. After cisplatin injection, cleaved
caspase-3 expression and the number of TUNEL-positive
cells were increased in both Parp1-KO and WT kidneys
(Figure 3a–c and Supplementary Figure S2 online).
To confirm our in vivo finding that PARP1 is involved
in necrosis, not apoptosis, during cisplatin nephrotoxicity,
we isolated primary proximal tubule epithelial cells from
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Figure 1 |Poly(ADP-ribose) polymerase 1 (PARP1) expression and activation are increased by cisplatin injection in kidneys.
The kidneys in Parp1-knockout (KO) and -wild-type (WT) 129S1/SvImJ male mice were harvested 0, 1, 2, 3, or 5 days after cisplatin
(20mg/kg body weight) injection (n¼ 6 in each group). (a) PARP1 expression and activation were examined by western blot analysis using
anti-PARP1 and anti-PAR antibody, respectively. Anti-b-actin antibody was used as a loading control. (b–d) The intensities of protein
bands (full length of PARP1, 116 kDa; cleaved PARP1, 89 kDa; PAR, 116 kDa; all approximate) were quantified using the Lab Works analysis
software. *Po0.05 vs. 0 days. ND, not detected.
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Parp1-KO and -WT kidneys. After treatment with 400 mmol/l
cisplatin for 8 h to induce necrosis, the percentage of
propidium iodide (PI)–positive WT cells was markedly
increased, but the PI staining was markedly reduced in
Parp1-KO cells (Figure 4a and Supplementary Figure S3a
online). Consistent with the in vivo results, Parp1-KO cells
showed significantly increased cellular ATP levels compared
with WT cells (Figure 4b). Further, the lactate dehydrogenase
release assay, which is a biochemical test of necrosis, showed
that Parp1-KO cells had significantly less necrosis, after
4 and 8 h of cisplatin treatment, compared with WT cells
(Figure 4c). After the treatment with 25 mmol/l cisplatin for
24 h to induce apoptosis, the percentage of TUNEL–positive
cells was increased with no significant difference in both
Parp1-KO and -WT cells (Figure 4d and Supplementary
Figure S3b online). Similarly, the cleaved caspase-3 expres-
sion induced by cisplatin treatment was not different in both
genotypes (Figure 4e and f). These in vivo and in vitro results
indicate that the loss of PARP1 reduces tubular cell necrosis,
but not apoptosis, during cisplatin nephrotoxicity.
Loss of PARP1 decreases kidney inflammation during
cisplatin nephrotoxicity
Inflammation is increased in the kidneys of cisplatin-injected
mice and is a major factor in the development of
kidney tissue damage and dysfunction.4,10 To determine
whether PARP1 upregulation contributes to this process, we
examined neutrophil infiltration. As shown in Figure 5a and
Supplementary Figure S4 online, prominent infiltration of
polymorphonuclear neutrophil (PMN)–positive neutrophils
occurred in WT kidneys after cisplatin injection. However,
Parp1-KO mice showed a significant reduction of interstitial
PMN-positive neutrophils in the cisplatin-injected kidneys.
As PARP1 activation leads to the expression of inflammatory
genes,14–16 we next confirmed this using western blot analysis.
WT mice showed an increase in the expression of ICAM-1,
TNF-a, and TLR4 in the kidney after cisplatin injection,
whereas loss of PARP1 markedly inhibited their expression
(Figure 5b–e). In addition, cytokine and chemokine expres-
sion in cisplatin-injected kidneys of Parp1-KO and -WT mice
was analyzed by real-time reverse-transcription polymerase
chain reaction. Cisplatin-induced upregulation of Il1b, Il6,
Il18, Ccl2, Ccl5, Cxcl1, and Cxcl10 gene was attenuated
in Parp1-KO mouse kidneys (Supplementary Figure S5
online). Taken together, these results suggest that loss of
PARP1 decreases neutrophil infiltration and expression of
several potent proinflammatory genes during cisplatin
nephrotoxicity.
Loss of PARP1 decreases MAPK and NF-jB activation
during cisplatin nephrotoxicity
Activation of c-Jun N-terminal kinases (JNK) and p38
mitogen-activated protein kinase (MAPK) is associated
with PARP1 signaling in various tissue/cell injuries23,24 and
stimulated by cisplatin in kidneys.25,26 Here, we tested
whether the cisplatin-induced activation of JNK and p38
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Figure 2 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency reduces kidney dysfunction, histological damage, and ATP depletion
induced by cisplatin injection in kidneys. The kidneys in Parp1-knockout (KO) and -wild-type (WT) male mice were harvested 0, 1, 2, 3,
or 5 days after cisplatin (20mg/kg body weight) injection. (a, b) Plasma creatinine and blood urea nitrogen (BUN) concentrations after
cisplatin injection (n¼ 6 in each group). (c, d) Histological damage in the cortex or outer medulla of hematoxylin and eosin (H&E)–stained
kidney sections was scored by counting the percentage of tubules that displayed tubular necrosis, cast formation, tubular dilation as
follows: 0¼ normal; 1¼o10%; 2¼ 10–25%; 3¼ 26–50%; 4¼ 51–75%; and 5¼475%. Ten fields ( 200 magnification) per kidney were used
for counting (n¼ 6 in each group). (e) Adenosine triphosphate (ATP) concentration after cisplatin injection (n¼ 4 in each group). *Po0.05
vs. 0 days, #Po0.05 vs. WT.
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MAPK signaling pathway in kidneys is mediated by PARP1
using western blot analysis. As shown in Figure 6a–e, phos-
phorylated JNK, p38 MAPK, MAPK kinase 3/6 (MKK3/6),
and MKK4 levels were increased in WT kidneys after cisplatin
injection. However, their activation was completely abolished
in Parp1-KO kidneys, indicating that the JNK and p38 MAPK
signaling pathways are regulated by PARP1 during cisplatin
nephrotoxicity.
Nuclear factor-kB (NF-kB) is activated in kidneys of
cisplatin-injected mice.27 PARP1 aggrandizes the activity
of NF-kB as a transcriptional cofactor and influences the
expression of many inflammatory genes.28 Next, we tested
whether PARP1 contributes to the activation of NF-kB
during cisplatin nephrotoxicity using western blot analysis.
As shown in Figure 7a–c, cisplatin-induced phosphorylation
of NF-kB p65/RelA was abrogated in Parp1-KO kidneys. WT
kidneys also revealed a decrease in IkBa expression after
cisplatin injection at 3 and 5 days, whereas Parp1-KO kidneys
had IkBa levels similar to that of controls. Thus, these results
suggest that the proinflammatory effect of PARP1 may be
linked to NF-kB activation, which may persist in cisplatin
nephrotoxicity.
To determine whether there is a hierarchy in the activation
of some of the key molecules involved in cisplatin injury,
we carried out pharmacological or genetic inhibition of the
various molecules using an in vitro system. Primary proximal
tubule epithelial cells from Parp1-KO and WT kidneys were
treated for 4 h with 400 mmol/l cisplatin and pharmacological
inhibitors of JNK, p38 MAPK, NF-kB, or TNF-a. TLR4
inhibition was achieved using a small interference RNA
approach. Appropriate controls were used for each experi-
ment. As shown in Figure 8, TLR4 or p38 MAPK inhibition
prevented cisplatin-induced TNF-a expression. Furthermore,
cisplatin-induced JNK, p38 MAPK, and NF-kB activation
were attenuated by TLR4 inhibition. Inhibitors of JNK, p38
MAPK, and NF-kB had no effect on the expression of each
other after cisplatin treatment. PARP1 expression was not
changed by any inhibitions after cisplatin treatment. Taken
together, these results suggest that PARP1 activation is
upstream of activation of these molecules, and PARP1
mediates TNF-a expression via the TLR4/p38 MAPK
signaling pathway in proximal tubule epithelial cells after
cisplatin injury.
Loss of PARP1 decreases oxidative stress during cisplatin
nephrotoxicity
As oxidative stress generation is involved in necrosis
induced by TNF-a and JNK,29 and has an important role
in cisplatin nephrotoxicity,30 we evaluated oxidative stress
levels in cisplatin-injected Parp1-KO and -WT kidneys
using lipid hydroperoxide assay and measuring the ratio of
reduced glutathione (GSH) to oxidized glutathione (GSSG).
WT kidneys showed a time-dependent increase of lipid
hydroperoxide concentration after cisplatin injection. By
comparison, Parp1-KO kidneys had significantly reduced
concentration (Figure 9a). Similarly, a reduction of the ratio
of GSH to GSSG by cisplatin was attenuated in Parp1-KO
kidneys compared with that in WT kidneys (Figure 9b).
These data suggest that loss of PARP1 reduces oxidative stress
generation during cisplatin nephrotoxicity, and the decreased
oxidative stress may partially account for the decreased
necrosis observed in cisplatin nephrotoxicity.
PARP1 inhibitor is protective against cisplatin-induced
nephrotoxicity and inflammation
As a PARP inhibitor is available, it is important to test
whether pharmacological inhibition of PARP1 attenuates
cisplatin-induced kidney injury, and thus explore a new
therapeutic approach for cisplatin nephrotoxicity. Therefore,
we administered N-(5,6-Dihydro-6-oxo-2-phenanthridinyl)-
2-acetamide hydrochloride (PJ34, a potent specific inhibitor
of PARP1) and monitored functional/histological damage
and inflammation induced by cisplatin in WT kidneys. At
3 and 5 days after cisplatin injection, plasma creatinine
and blood urea nitrogen concentrations in PJ34-treated mice
were significantly lower than those in vehicle-treated mice
(Figure 10a and b). Similarly, the score of histological damage
in tubular epithelial cells of the cortex and outer medulla
after cisplatin injection was significantly reduced in PJ34-
treated mice compared with that in vehicle-treated mice
(Figure 10c and d, and Supplementary Figure S6a online).
Notably, PJ34 inhibited cisplatin-induced infiltration of
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Figure 3 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency
does not affect apoptosis induced by cisplatin injection in
kidneys. The kidneys in Parp1-knockout (KO) and -wild-type (WT)
male mice were harvested 0, 1, 2, 3, or 5 days after cisplatin
(20mg/kg body weight) injection. (a) Cleaved caspase-3
expression was examined by western blot analysis. Anti-b-actin
antibody was used as a loading control. The expression of cleaved
caspase-3 was not significantly changed in Parp1-KO mouse
kidneys compared with WT mouse kidneys at each time point.
(b) The intensities of protein bands (B17 kDa) were quantified
using the Lab Works analysis software. (c) Terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL)–positive
cells were counted in 10 fields ( 200 magnification) per kidney
(n¼ 4 in each group). The number of TUNEL-positive cells was not
significantly changed in Parp1-KO mouse kidneys compared with
WT mouse kidneys at each time point. *Po0.05 vs. 0 days.
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Figure 4 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency reduces necrosis, not apoptosis, induced by cisplatin treatment in
primary culture of proximal tubule epithelial cells. The proximal tubule epithelial cells were isolated from Parp1-knockout (KO) and
-wild-type (WT) mouse kidneys, respectively. After 18 h of starvation, the cells were treated with 400 mmol/l cisplatin for 8 h to induce
necrosis (a, b, c) and 25mmol/l cisplatin for 24 h to induce apoptosis (d, e, f), respectively. Dimethyl sulfoxide (DMSO) was used as vehicle.
(a) The percentage of propidium iodide (PI)–positive cells was counted in five fields ( 400 magnification) per well on 12-well plates (n¼ 4
in each group). (b) Intracellular adenosine triphosphate (ATP) concentration after cisplatin or vehicle treatment in 100-mm dishes (n¼ 4 in
each group). (c) Lactate dehydrogenase (LDH) release was measured for 0, 2, 4, and 8 h of cisplatin treatment in 24-well plates (n¼ 6 in each
group). (d) The percentage of transferase dUTP nick end labeling (TUNEL)-positive cells was counted in five fields ( 400 magnification) per
well (n¼ 4 in each group). The percentage of TUNEL-positive cells was not significantly changed in Parp1-KO cells compared with WT cells.
(e) Cleaved caspase-3 expression was examined by western blot analysis. Anti-b-actin antibody was used as a loading control. (f) The
intensities of protein bands (B17 kDa) were quantified using the Lab Works analysis software. The expression of cleaved caspase-3 was not
significantly changed in Parp1-KO cells compared with WT cells at each time point. *Po0.05 vs. vehicle or 0 h, #Po0.05 vs. WT.
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Figure 5 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency inhibits inflammation induced by cisplatin injection in kidneys. The
kidneys in Parp1-knockout (KO) and -wild-type (WT) male mice were harvested 0, 1, 2, 3, or 5 days after cisplatin (20mg/kg body weight) or
saline (control) injection. (a) Polymorphonuclear neutrophil (PMN)–positive cells were counted in 10 fields ( 200 magnification) per kidney
(n¼ 4 in each group). (b) The expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-a (TNF-a), and Toll-like
receptor 4 (TLR4) in kidneys was examined by western blot analysis. Anti-b-actin antibody was used as a loading control. (c–e) The
intensities of protein bands (ICAM-1, 110 kDa; TNF-a, 26 kDa; TLR4, 90 kDa; all approximate) were quantified using the Lab Works analysis
software (n¼ 6 in each group). *Po0.05 vs. 0 days, #Po0.05 vs. WT.
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neutrophils (Figure 11a and Supplementary Figure S6b
online) and expression of proinflammatory proteins includ-
ing ICAM-1, TNF-a, and TLR4 in kidneys (Figure 11b–e).
These results indicate that PJ34, which effectively inhibited
PARP1 activation (Figure 11b and f), is protective against
cisplatin-induced kidney injury, suggesting a feasible thera-
peutic strategy to prevent cisplatin nephrotoxicity.
DISCUSSION
Cisplatin acute kidney injury is associated with renal
dysfunction, tubular cell injury and death, and tissue damage.
Despite having been the focus of active investigation for
many decades, there exists a gap in our understanding of the
exact pathogenesis of cisplatin nephrotoxicity. Recent studies
have emphasized on inflammation and apoptosis, considered
to be the major contributors of tissue injury. Our data
demonstrate the novel finding that inhibition of necrotic cell
death and inflammation prevents cisplatin nephrotoxicity
even when apoptosis persists. These data suggest that necrosis
and inflammation are major determinants of cisplatin
nephrotoxicity, supported by the finding that the predomi-
nant lesion is acute necrosis in patients with cisplatin acute
kidney injury.31
Tubular cell death by apoptosis and necrosis is the main
histopathological characteristic of cisplatin nephrotoxicity.4
In particular, it has been recognized that proximal tubular
cells are the major site of cell death during cisplatin
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Figure 6 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency suppresses JNK and p38 MAPK activation induced by cisplatin
injection in kidneys. The kidneys in Parp1-knockout (KO) and -wild-type (WT) male mice were harvested 0, 1, 2, 3, or 5 days after cisplatin
injection. (a) Phosphorylated c-Jun N-terminal kinase (JNK) at Thy183/Tyr185 (p-JNK), JNK, phosphorylated p38 mitogen-activated protein
kinase (MAPK) at Thr180/Tyr182 (p-p38), p38, phosphorylated MAPK kinase 3/6 at Ser189/207 (p-MKK3/6), and phosphorylated MKK4 at
Thr261 (p-MKK4) were examined by western blot analysis. Anti-b-actin antibody was used as a loading control. (b–e) The intensities of
protein bands (p-MKK3/6, 40 kDa; p-JNK and JNK, 46 and 55 kDa; p-MKK4, 46 kDa; p-p38 and p38, 38 kDa; all approximate) were quantified
using the Lab Works analysis software (n¼ 6 in each group). *Po0.05 vs. 0 days; #Po0.05 vs. WT.
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Figure 7 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency
suppresses NF-jB phosphorylation induced by cisplatin
injection in kidneys. The kidneys in Parp1-knockout (KO) and
-wild-type (WT) male mice were harvested 0, 1, 2, 3, or 5 days after
cisplatin (20mg/kg body weight) injection. (a) Phosphorylated
nuclear factor-kB (NF-kB) RelA at Ser276 (p-RelA), RelA, and IkBa
were examined by western blot analysis. Anti-b-actin antibody
was used as a loading control. (b, c) The intensities of protein
bands (p-RelA and RelA, 65 kDa; IkBa, 39 kDa; all approximate)
were quantified using the Lab Works analysis software (n¼ 6 in
each group). *Po0.05 vs. 0 days; #Po0.05 vs. WT.
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nephrotoxicity.32,33 Early observations by Lieberthal et al.6
and Shino et al.33 have demonstrated that the apoptotic or
necrotic cell death is dependent on the cisplatin concen-
tration and duration of treatment. Apoptosis occurs upon
low concentrations of cisplatin for a long time, whereas
necrosis is observed at high concentrations of cisplatin for a
short time. In our studies using primary cultures of proximal
tubule epithelial cells, loss of PARP1 prevents necrosis
induced by an 8-h exposure to 400 mmol/l cisplatin, but not
apoptosis by a 24-h exposure to 25 mmol/l cisplatin. This is
consistent with our in vivo results, suggesting that PARP1-
dependent tubular necrosis is a principal factor in cisplatin
nephrotoxicity and causes subsequent kidney dysfunction.
Although some of the earlier reports suggested the involve-
ment of PARP1 in the apoptotic pathway,34,35 the majority
of the studies, including ours, provide evidence that PARP1
upregulation induces necrosis in various cell/tissue injury
models.17,22,36,37
During cisplatin nephrotoxicity, necrosis may not be
exclusively due to ATP depletion, as our data demonstrate
increased oxidative stress levels in cisplatin-injected WT
kidneys compared with Parp1-KO kidneys using lipid hydro-
peroxide assay and measuring the ratio of GSH to GSSG.
Reactive oxygen species (ROS) production is induced by
mitochondrial complex I via PARP1 overactivation during
ischemia and reperfusion injury,38 and poly (ADP-ribosyl)ated
mitochondrial proteins including components of the electron
transport chain could further increase ROS production.39,40
In particular, cytochrome P450 2E1 expressed in kidney
proximal tubules is suggested to be involved in the generation
of ROS during cisplatin nephrotoxicity.30 The increased
ROS damages DNA and further induces PARP1 activation,
leading to a positive feedback mechanism to exacerbate
necrotic cell death.
The cisplatin-induced inflammatory response results in
the development of kidney tissue damage and kidney dys-
function, which cause acute kidney injury.10,11 Recent evi-
dence indicates upregulation of various inflammatory genes
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Figure 9 |Poly(ADP-ribose) polymerase 1 (Parp1) deficiency
reduces oxidative stress induced by cisplatin injection in
kidneys. The kidneys in Parp1-knockout (KO) and -wild-type (WT)
male mice were harvested 0, 1, 2, 3, or 5 days after cisplatin
(20mg/kg body weight) injection. (a, b) Lipid hydroperoxide
concentration and ratio of reduced glutathione (GSH) to oxidized
glutathione (GSSG) were measured using kits (see Materials
and Methods; n¼ 4 in each group). *Po0.05 vs. 0 days; #Po0.05
vs. WT.
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including TNF-a, ICAM-1, TLR4, IL-1b, IL-6, IL-18,
monocyte chemotactic protein-1, keratinocyte-derived
chemokine, and interferon g–inducible protein 10 during
cisplatin nephrotoxicity.10,11,41–43 Our studies indicate that
this inflammatory response is most likely mediated through
PARP1. Previously, genetic deletion or pharmacological
inhibition of PARP1 has been shown to suppress neutrophil
infiltration and upregulation of ICAM-1, TLR4, and
cytokines in local or systemic inflammatory disease.14,15,44
Our recent studies revealed attenuated neutrophil infiltration
and TNF-a expression in kidney ischemia and reperfusion
injury, and unilateral ureteral obstruction of Parp1-KO
mice.22,37 Consistent with previous reports, our present data
show that loss of PARP1 results in the reduced expression of
proinflammatory proteins and cytokine/chemokine mRNAs,
as well as inhibition of the neutrophil infiltration in cisplatin-
injected kidneys, suggesting that endogenous PARP1-depen-
dent inflammation contributes to kidney structural and
functional damage during cisplatin nephrotoxicity.
Damaged tubules can release alarming factors such as
high-mobility group box 1 to activate inflammatory
response.45 However, high-mobility group box 1 does not
have a significant role in cellular responses to cisplatin.46 On
the other hand, TNF-a triggers necrosis and apoptosis,
as well as inflammation.47 In particular, TNF-a is pivotal to
the kidney inflammatory response induced by cisplatin. The
production of TNF-a is increased during cisplatin nephro-
toxicity,10 and inhibition of TNF-a using pharmaco-
logical inhibitors and gene deletion suppresses leukocyte
infiltration and expression of other cytokine/chemokine
and ICAM-1.10,25 In addition, loss of TNF-a receptor 1
prevents cisplatin-induced kidney injury possibly by attenu-
ating inflammation and cell death.48 Our findings demon-
strate that, upon cisplatin treatment, Parp1-deficient mouse
kidneys show significant attenuation of TNF-a expression,
subsequent cytokine/chemokine production, and ICAM-1
expression, suggesting that TNF-a expression is regulated
by PARP1 in cisplatin kidney injury. Interestingly, we have
found that the apoptotic mechanism proposed to be acti-
vated by TNF-a in promoting cisplatin injury is not affected
in Parp1-KO kidneys after cisplatin injection. A recent report
using Tlr4-KO mice has established that TLR4 promotes
kidney inflammation and tissue injury through the p38
MAPK/TNF-a pathway.11 Our data demonstrate that
cisplatin-induced TLR4 expression is notably suppressed in
Parp1-KO kidneys. Taken together, these data suggest that
PARP1 functions upstream of TNF-a and TLR4 where it
regulates the expression of these genes, as well as downstream
signaling events.
NF-kB is a transcription factor activated by inducers such
as TNF-a in cisplatin nephrotoxicity. NF-kB activation
induces the expression of a number of cytokines, chemo-
kines, cell adhesion molecules, and receptors implicated in
the kidney diseases.27,49,50 In addition, indirect inhibition of
NF-kB correlates with attenuation of cisplatin nephro-
toxicity.27 The NF-kB1 subunit directly binds to PARP1 in
response to a stressor, and PARP1 inhibitor reduces the
DNA-binding activity of NF-kB and subsequently lowers its
transcriptional activity.51,52 The reduced activity of NF-kB
leads to decreased TNF-a and ICAM-1 expression in several
diverse cell types,15,28,52 suggesting that PARP1 participates in
augmenting the transcriptional activity of NF-kB. Consistent
with the pattern of TNF-a, TLR4, ICAM-1, and cytokine/
chemokine expression in our present study, NF-kB activation
induced by RelA phosphorylation and IkBa degradation after
cisplatin injection is completely abolished in Parp1-KO
kidneys, suggesting that endogenous PARP1 regulates
NF-kB activity during cisplatin nephrotoxicity.
The MAPK pathway is activated by cisplatin in kidney
ephithelial cells.25,26,53 Of the major MAPK pathway
effectors, p38 and JNK pathways contribute to cell death
and inflammation through stimulating factors such as cyto-
kines.54 Respective pharmacological inhibitors of p38 and
JNK are shown to be renoprotective in cisplatin-induced
nephrotoxicity.25,26 PARP1 is involved in p38 and JNK
activation in various cell injury models.23,55,56 Here, our data
reveal that cisplatin-induced activation of p38 and JNK is
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Figure 10 |Poly(ADP-ribose) polymerase 1 (PARP1) inhibitor
reduces kidney dysfunction and histological damage induced
by cisplatin injection in kidneys. The kidneys in 129S1/SvImJ
male mice were harvested 0, 3, or 5 days after cisplatin injection.
The mice were administered either PJ34 (10mg/kg body weight)
or saline (control) twice daily intraperitoneally from 24 h before
cisplatin injection up to the time that they were killed.
(a, b) Plasma creatinine and blood urea nitrogen (BUN)
concentrations after cisplatin injection (n¼ 4 in each group).
(c, d) Histological damage in the cortex or outer medulla of H&E-
stained kidney sections was scored by counting the percentage
of tubules that displayed tubular necrosis, cast formation, and
tubular dilation as follows: 0¼ normal; 1¼o10%; 2¼ 10–25%;
3¼ 26–50%; 4¼ 51–75%; and 5¼475%. Ten fields ( 200 magni-
fication) per kidney were used for counting (n¼ 4 in each group).
*Po0.05 vs. 0 days, #Po0.05 vs. control.
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completely blunted in Parp1-KO kidneys. It is also known
that the activation of p38 and/or JNK contributes to TNF-a
production in response to cisplatin and other injury,11,57–59
suggesting that the blockade of kidney p38 and/or JNK
activation in Parp1-KO kidneys is consistent with a role of
PARP1 in TNF-a production through MAPK activation
during cisplatin nephrotoxicity. To our knowledge, a master
regulator of the variety of events including necrosis and
inflammation in cisplatin nephrotoxicity has not yet been
identified. Our data show that inflammatory gene expression,
JNK/p38 MAPK activation, and oxidative stress by cisplatin
are induced earlier than initiation of ATP depletion, and their
induction is blocked by loss of PARP1. These data suggest
that loss of PARP1 contributes to the protection of kidney
function and histological damage in the early phase of
cisplatin nephrotoxicity by the inhibition of inflammation,
MAPK activation, and oxidative stress, but not ATP
depletion. Thus, PARP1 may be a master regulator that
modulates the activity of various inflammatory cytokines and
MAPKs in the development of cisplatin nephrotoxicity. To
further define the hierarchy of activation of the various
inflammatory molecules and MAPKs as a function of PARP1
in the setting of cisplatin injury, we carried out in vitro study
using small interference RNA or pharmacological inhibitors
of each molecule. Our data demonstrate that PARP1-induced
TLR4 expression activates p38 MAPK, leading to TNF-a
expression. Thus, a PARP1-TLR4-p38 MAPK-TNF-a axis
exists in kidney proximal tubular cells after cisplatin injury
and may contribute to the induction of lactate dehydrogenase
release as TNF-a increases lactate dehydrogenase release
in proximal tubule epithelial cells.60 The activation of
NF-kB and JNK is independent of each other or the
expression of TLR4, p38 MAPK, and TNF-a. However, their
expression or activation was dependent on PARP1 expres-
sion. A role for JNK1 in PARP1 activation was previously
reported;61 however, it is not evident from our data that such
a feedback mechanism exists in kidney tubular cells after
cisplatin injury.
In an attempt to investigate the usefulness of PARP1
deletion in a translational setting, we tested the efficacy of
PJ34, a pharmacological inhibitor of PARP1, in its ability to
protect against injuries induced by cisplatin. As expected, our
present findings demonstrate that treatment with the PARP1
inhibitor markedly attenuates cisplatin-induced kidney
dysfunction, histological damage, and proinflammatory gene
expression. This is consistent with the results in Parp1-KO
kidneys, and data from previous reports in cell or tissue
injury,24,33 suggesting PARP modulation as a novel thera-
peutic target in cisplatin nephrotoxicity. In summary, the
results of this study show that PARP1 activation in cisplatin-
injected kidneys may integrate several pathways that converge
to induce cellular necrosis and inflammation. Targeting
PARP1 may constitute a viable strategy for the treatment of
cisplatin nephrotoxicity.
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Figure 11 |Poly(ADP-ribose) polymerase 1 (PARP1) inhibitor reduces inflammation induced by cisplatin injection in kidneys.
The kidneys in 129S1/SvImJ male mice were harvested 0, 3, or 5 days after cisplatin injection. The mice were administered either PJ34
(10mg/kg body weight) or saline (control, Con) twice daily intraperitoneally from 24 h before cisplatin injection up to the time that
they were killed. (a) Polymorphonuclear neutrophil (PMN)-positive cells were counted in 10 fields ( 200 magnification) per kidney (n¼ 4 in
each group). (b) The expression of Poly(ADP-ribose) (PAR), intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-a (TNF-a),
and Toll-like receptor 4 (TLR4) in kidneys was examined by western blot analysis. Anti-b-actin antibody was used as a loading control.
(c–f) The intensities of protein bands (PAR, 116 kDa; ICAM-1, 110 kDa; TNF-a, 26 kDa; TLR4, 90 kDa; all approximate) were quantified using the
Lab Works analysis software (n¼ 4 in each group). *Po0.05 vs. 0 days; #Po0.05 vs. control.
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MATERIALS AND METHODS
Cisplatin nephrotoxicity in vivo and in vitro
See Supplementary Methods online.
Western blot analysis
Western blot analysis was confirmed, as described previously,62–64
using antibodies against PARP1, cleaved caspase-3, phospho-RelA,
phospho-p38, phospho-38, phospho-JNK, JNK, phospho-MKK3/6,
phospho-MKK4 (Cell Signaling, Beverly, MA), ICAM-1, RelA, IkBa
(Santa Cruz, Santa Cruz, CA), PAR (BD Pharmingen, San Jose, CA),
b-actin (Sigma, St. Louis, MO), TNF-a (Abcam, Cambridge, MA),
or TLR4 (Imgenex, San Diego, CA). Band intensities were analyzed
using the LabWorks software (Ultra-Violet Products, Cambridge, UK).
Histology, immunohistochemistry, and TUNEL assay
Histological damage in the cortex or outer medulla of H&E-stained
kidney sections was scored by percentage of tubules that displayed
tubular necrosis, cast formation, and tubular dilation as previously
described.22,65,66 Necrotic cell death was scored by assessing the
percentage of tubules with increased eosinophilia, cytoplasmic
vacuolization, or loss of architecture and nucleus as previously
reported.67 Immunohistochemistry for neutrophils was performed
with a polyclonal anti-PMN antibody (Accurate, Westbury, NY)
followed by a HRP-conjugated goat anti-rabbit IgG (Vector
Laboratories, Burlingame, CA).22 Cisplatin- or vehicle-treated cells
were stained with 1 mg/ml PI for 10 min, and the percentage of
PI-positive cells was counted by fluorescence microscopy.5 TUNEL
assay in the kidneys and cells was carried out using the In Situ Cell
Death Detection kit, Fluorescein (Roche, Mannheim, Germany),
as described previously.68–70
ATP, glutathione, and lipid hydroperoxide assay
ATP, gluthathione, and lipid hydroperoxide assays were performed
in the kidney or cell extracts using kits (BioVision, Mountain View,
CA) according to manufacturer’s instructions.
Real-time reverse-transcription polymerase chain reaction
See Supplementary Methods online.
Statistics
Values are reported as mean±s.e. Statistical differences among
groups were calculated using analysis of variance followed by a least
significant difference post hoc comparison using the SPSS 12.0
program (SPSS, Chicago, IL). Differences between groups were con-
sidered statistically significant at a P-value of o0.05.
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Figure S1. Parp1 deficiency reduces histological damage induced by
cisplatin injection in kidneys.
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Figure S3. Parp1 deficiency reduces necrosis, not apoptosis, induced
by cisplatin treatment in primary culture of proximal tubule epithelial
cells.
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